CN114159332A - Liposome composition and preparation method thereof - Google Patents
Liposome composition and preparation method thereof Download PDFInfo
- Publication number
- CN114159332A CN114159332A CN202111408251.XA CN202111408251A CN114159332A CN 114159332 A CN114159332 A CN 114159332A CN 202111408251 A CN202111408251 A CN 202111408251A CN 114159332 A CN114159332 A CN 114159332A
- Authority
- CN
- China
- Prior art keywords
- liposome composition
- liposome
- bilayer
- tetraspanin
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 36
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims abstract description 22
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 18
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 16
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 16
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 16
- 229940067606 lecithin Drugs 0.000 claims abstract description 16
- 235000010445 lecithin Nutrition 0.000 claims abstract description 16
- 239000000787 lecithin Substances 0.000 claims abstract description 16
- 108700031126 Tetraspanins Proteins 0.000 claims abstract description 8
- 102000043977 Tetraspanins Human genes 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000036571 hydration Effects 0.000 claims abstract description 6
- 238000006703 hydration reaction Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims 2
- 238000000527 sonication Methods 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 abstract description 14
- 102100025222 CD63 antigen Human genes 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940036350 bisabolol Drugs 0.000 description 3
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 125000002138 bisabolol group Chemical group 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a liposome composition and a preparation method thereof, comprising a bilayer; the bilayer comprises lecithin, cholesterol, glycoprotein and tetraspanin CD 63; the preparation method of the liposome composition comprises the following steps: mixing lecithin, cholesterol, glycoprotein and tetraspanin CD63, adding a solvent for dissolving, volatilizing the solvent, adding pure water for hydration, and performing ultrasonic treatment to obtain a liposome composition; the liposome composition contains tetraspanin CD63, can improve stability of liposome composition, has transdermal property of exosome, and can be used in skin care field.
Description
Technical Field
The invention relates to a liposome composition and a preparation method thereof, belonging to the technical field of functional compositions.
Background
Transdermal absorption of cosmetics refers to a process in which functional ingredients in cosmetics act on the surface of the skin or enter different skin layers such as epidermis or dermis according to the effectiveness of the product, and accumulate and act at the site. The physiological structures of cosmetic transdermal absorption mainly include the stratum corneum, hair follicles, sebaceous glands and sweat ducts. The pathways of penetration through the stratum corneum can be divided into two categories: intercellular and transcellular pathways. It is generally believed that the primary barrier to transdermal penetration is from the stratum corneum. Research shows that in an in vitro transdermal experiment, after the skin stratum corneum is stripped, the permeability of the substance can be increased by tens of times or even hundreds of times. Drugs with small molecular mass diffuse into the largest absorbed barrier stratum corneum, although in limited amounts, with the rate of diffusion increasing further inward. The diffusion pathways in the stratum corneum are both intercellular diffusion and cell membrane diffusion. It is generally accepted that lipid-soluble, non-polar materials diffuse readily through the intercellular lipid bilayer, while water-soluble and polar materials diffuse readily through keratinocytes.
The liposome (hollow) prepared from lecithin, ceramide and the like has a bilayer structure which is the same as that of a skin cell membrane structure and has an encapsulation effect, and the liposome for encapsulating moisturizing substances such as hyaluronic acid, polyglucoside and the like is a more excellent moisturizing substance, has an excellent moisturizing effect on the skin and is beneficial to the skin to obtain nutritional or functional components through transdermal absorption. However, the liposome has larger molecular size difference, and the smaller the molecule is, the stability of the liposome cannot be ensured, and the functions are gradually weakened.
Disclosure of Invention
In order to overcome the defects of the prior art, the first object of the invention is to provide a liposome composition, which contains a tetraspanin protein CD63, can improve the stability of the liposome composition, enables the liposome composition to have the transdermal performance of exosome, and can be used in the field of skin care.
A second object of the present invention is to provide a method for preparing the liposome composition, which can maintain the stability of the liposome.
The third purpose of the invention is to provide an application of the liposome composition.
The first purpose of the invention can be achieved by adopting the following technical scheme: a liposome composition comprising a bilayer; the bilayer includes lecithin, cholesterol, glycoproteins, and the tetraspanin protein CD 63.
Further, the bilayer comprises the following components in parts by weight:
further, the bilayer comprises the following components in parts by weight:
further, the liposome composition further comprises an active ingredient; the bilayer encapsulates the active ingredient.
Further, the active ingredient is an oil-soluble active ingredient.
Further, the oil-soluble active ingredient is bisabolol.
Further, the weight portion of the active ingredients is 0.1-9 portions.
Furthermore, the particle size of the liposome is a, and a is more than 0 and less than or equal to 100 nm.
The second purpose of the invention can be achieved by adopting the following technical scheme: a method for preparing liposome composition comprises mixing lecithin, cholesterol, glycoprotein and tetraspanin CD63, adding solvent for dissolving, volatilizing solvent, adding pure water for hydration, and ultrasonic processing to obtain liposome composition.
Further, mixing lecithin, cholesterol, glycoprotein and tetraspanin CD63, adding chloroform for dissolving, volatilizing chloroform, adding pure water for hydration, and performing 400W ultrasonic treatment to obtain the liposome composition.
The third purpose of the invention can be achieved by adopting the following technical scheme: the liposome composition as described above is used for application to the skin.
Compared with the prior art, the invention has the beneficial effects that:
1. the liposome composition of the invention combines lecithin, cholesterol, glycoprotein and tetraspanin CD63 to form a bilayer, can be directly used or used for coating various active ingredients and maintaining the performance of the active ingredients;
2. the liposome composition has small particle size, good stability, similar property and transdermal performance to exosome, can be used in the field of skin care, and is beneficial to skin to absorb active ingredients;
3. the preparation method of the invention ensures that the bilayer uniformity of the liposome composition is good, and the formed liposome has smaller particle size but better stability.
Detailed Description
The invention will be further described with reference to specific embodiments:
a liposome composition comprises liposome and active ingredient; the liposome coats the active ingredient;
the bilayer of the liposome comprises the following components in parts by weight:
wherein the active ingredient is an oil-soluble active ingredient;
wherein, the weight portion of the active ingredients is 0.1 to 9 portions;
wherein the particle size of the liposome is a, and a is more than 0 and less than or equal to 100 nm.
The preparation method of the liposome composition comprises the following steps: mixing lecithin, cholesterol, glycoprotein, tetraspanin CD63 and active ingredients, adding chloroform for dissolving, volatilizing chloroform, adding pure water for hydration, and carrying out 400W ultrasonic treatment to obtain the liposome composition. The preparation method ensures that the liposome composition has good bilayer uniformity and good wrapping property, the particle size a is more than 0 and less than or equal to 100nm, and good stability and coating performance are kept.
The liposome composition can be used alone or stably existing in emulsion system such as aqua, emulsion cream, etc., and can be used for applying on skin such as face, neck, abdomen, etc.
Exosomes are smaller sized liposomes secreted by cells. Since exosomes themselves have certain instability and cannot be stored in cosmetics for a long time, exosomes are hardly directly applied in cosmetics. An artificial exosome is prepared from lecithin, cholesterol, glycoprotein and the tetraspanin protein CD63, the tetraspanin protein CD63 being a member of the tetraspanin superfamily of proteins, also known as classical exosome markers in exosome cell membranes. Experimental results show that expression of knockout CD63 reduces secretion of smaller diameter extracellular vesicles (exosomes) but does not affect secretion of directly larger extracellular vesicles, indicating that CD63 controls and regulates the size and formation of liposome compositions. Further analysis shows that CD63 can regulate cell membrane bending when the cell exosome generates bubble formation, thereby influencing the size of the cell exosome. In addition, CD63 also plays an important role in stabilizing liposome compositions and cell recognition. In the present invention, the particle size of the liposome composition can be effectively controlled by introducing CD 63.
The glycoprotein used in the invention is a molecule formed by covalently linking an exosome membrane protein and an oligosaccharide chain through glycosylation, wherein two modes of Glycosyl Phosphatidylinositol (GPI) anchoring glycosylation and N-glycosylation are included. On one hand, the glycosylation modification is involved in cell recognition, and has remarkable targeting capability as a surface marker of a specific cell; on the other hand, the rejection reaction of human immune cells can be obviously reduced, so that the constructed liposome composition has higher biocompatibility.
The liposome composition disclosed by the invention is combined and used by lecithin, cholesterol, glycoprotein and tetraspanin CD63 to form a bilayer, so that various active ingredients can be effectively coated, and the performance of the active ingredients is maintained; the liposome has a particle size a of 0-100 nm, good stability, and good properties of exosome and transdermal property.
Examples 1-3 and comparative examples 1-2:
a liposome composition comprises liposome and active ingredient; the liposome coated the active ingredient, and the weight parts of the bilayer and the active ingredient of the liposome are shown in table 1:
TABLE 1 Liposomal Components parts by weight of examples 1-2 and comparative examples 1-2
| Bilayer composition | Example 1 | Example 2 | Example 3 | Comparative example 1 | Comparative example 2 |
| Lecithin | 85 | 88.5 | 82 | 89.5 | 85 |
| Cholesterol | 5 | 8 | 6 | 0 | 5 |
| Glycoprotein | 1 | 3.9 | 3 | 5 | 5 |
| Tetraspanin protein CD63 | 0.5 | 0.4 | 0.8 | 0.5 | 0 |
| Active ingredient (bisabolol) | 8.5 | 0.15 | 6 | 5 | 5 |
The total mass of the liposomes was 300 mg.
The preparation method of the liposome composition comprises the following steps: mixing lecithin, cholesterol, glycoprotein, tetraspanin CD63 and bisabolol, adding 8mL of chloroform for dissolving, volatilizing chloroform, adding 10mL of pure water for hydrating for 30min, stirring at 35 ℃ for 1h, and performing 400W ultrasonic treatment for 10min to obtain the liposome composition. The particle size of the nanoliposomes was evaluated using a Zetasizer3000SH laser particle sizer (Malvern Instruments Ltd) to test the particle size of the resulting nanoliposomes. The results are shown in table 2:
table 2 particle size of examples and comparative examples
From the test results, it is known that when lecithin, cholesterol, glycoprotein, tetraspanin CD63 are used together, stable liposomes having a particle size of less than 100nm can be obtained. Meanwhile, the cholesterol and the four-transmembrane protein CD63 play a key role in the process of regulating the particle size of the liposome, the cholesterol can improve the fluidity of a liposome membrane system, and the four-transmembrane protein CD63 can regulate the bending efficiency of a cell membrane. When cholesterol is not present in the composition or the tetraspanin CD63 is not present, the liposome size rapidly increases and liposomes having a particle size of less than 100nm cannot be formed efficiently. Therefore, the four components are combined to be used, so that the particle size of the liposome can be synergistically and effectively adjusted.
Various other changes and modifications to the above-described embodiments and concepts will become apparent to those skilled in the art from the above description, and all such changes and modifications are intended to be included within the scope of the present invention as defined in the appended claims.
Claims (10)
1. A liposome composition comprising a bilayer; the bilayer includes lecithin, cholesterol, glycoproteins, and the tetraspanin protein CD 63.
2. The liposome composition of claim 1, wherein the bilayer comprises the components in parts by weight:
3. the liposome composition of claim 2, wherein the bilayer comprises the components in parts by weight:
4. the liposome composition of claim 1, further comprising an active ingredient; the bilayer encapsulates the active ingredient.
5. The liposome composition of claim 4, wherein the active ingredient is an oil-soluble active ingredient.
6. The liposome composition of claim 4, wherein the active ingredient is present in an amount of 0.1 to 9 parts by weight.
7. The liposome composition of claim 1, wherein the liposome has a particle size a, 0 < a ≦ 100 nm.
8. A method for preparing a liposome composition is characterized in that lecithin, cholesterol, glycoprotein and tetraspanin CD63 are mixed, a solvent is added for dissolution, then the solvent is volatilized, pure water is added for hydration, and ultrasonic treatment is carried out, so as to obtain the liposome composition.
9. The method for preparing the liposome composition of claim 8, wherein the liposome composition is obtained by mixing lecithin, cholesterol, glycoprotein and tetraspanin CD63, adding chloroform for dissolution, volatilizing chloroform, adding pure water for hydration, and performing 400W sonication.
10. Use of a liposome composition according to claim 1 for application to the skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111408251.XA CN114159332B (en) | 2021-11-24 | 2021-11-24 | Liposome composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111408251.XA CN114159332B (en) | 2021-11-24 | 2021-11-24 | Liposome composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114159332A true CN114159332A (en) | 2022-03-11 |
| CN114159332B CN114159332B (en) | 2023-11-10 |
Family
ID=80480694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111408251.XA Active CN114159332B (en) | 2021-11-24 | 2021-11-24 | Liposome composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114159332B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1443529A (en) * | 2003-04-15 | 2003-09-24 | 华南理工大学 | Liposome enveloping fruit acid, its preparation method and application |
| CN1814294A (en) * | 2005-11-29 | 2006-08-09 | 沈阳农业大学 | Corn SOD liposome and its preparing method |
| CN102302416A (en) * | 2011-08-26 | 2012-01-04 | 广州佳禾化妆品制造有限公司 | Coenzyme Q-10/EGF liposome, preparation method and application |
| CN111759809A (en) * | 2020-07-13 | 2020-10-13 | 南京启医科技有限公司 | Vesicle and preparation method and application thereof |
-
2021
- 2021-11-24 CN CN202111408251.XA patent/CN114159332B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1443529A (en) * | 2003-04-15 | 2003-09-24 | 华南理工大学 | Liposome enveloping fruit acid, its preparation method and application |
| CN1814294A (en) * | 2005-11-29 | 2006-08-09 | 沈阳农业大学 | Corn SOD liposome and its preparing method |
| CN102302416A (en) * | 2011-08-26 | 2012-01-04 | 广州佳禾化妆品制造有限公司 | Coenzyme Q-10/EGF liposome, preparation method and application |
| CN111759809A (en) * | 2020-07-13 | 2020-10-13 | 南京启医科技有限公司 | Vesicle and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 赵嘉兰，等: "内源性外泌体作为药物递释系统的研究进展", vol. 31, no. 7, pages 160 - 165 * |
| 邵钰柔，等: "细胞外囊泡的表面修饰及其在中药活性成分递送中的应用", vol. 36, no. 4, pages 561 - 566 * |
| 高方园，等: "外泌体分离技术及其临床应用研究进展", vol. 37, no. 10, pages 1071 - 1083 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114159332B (en) | 2023-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| van Hoogevest et al. | Phospholipids in cosmetic carriers | |
| JP4203394B2 (en) | Micronized liposomes containing a high concentration of triterpenoid and method for producing the same | |
| US8029810B2 (en) | Water-based delivery systems | |
| Parashar et al. | Ethosomes: a recent vesicle of transdermal drug delivery system | |
| JP4237446B2 (en) | Method for stabilizing nano-emulsified particles using tocopherol derivative and skin external preparation composition containing nano-emulsified particles | |
| CA2063862C (en) | Topical preparation containing a suspension of solid lipid particles | |
| KR102037354B1 (en) | Nano-lipid carrier for encapsulation of physiologically active substance and preparation method thereof | |
| CH668181A5 (en) | COMPOSITION FOR COSMETIC OR PHARMACEUTICAL USE CONSISTING OF A DISPERSION OF LIQUID SPHERULES. | |
| CN106619149A (en) | Method for preparing nicotinamide-coated multivesicular liposomes | |
| Sangeetha | Ethosomes: A novel drug delivery system and their therapeutic applications-A review | |
| EP2769709B1 (en) | Pseudolipid complex mixture and a skin external application composition containing same | |
| CN113425620A (en) | Liposome for wrapping active component, preparation method and application thereof | |
| WO2006039667A2 (en) | Water-based delivery systems | |
| US20030017183A1 (en) | Dermatological suspensions(micro-matrix) | |
| KR102190935B1 (en) | Nano-lipid carrier for encapsulation of physiologically active substance and preparation method thereof | |
| CN114159332B (en) | Liposome composition and preparation method thereof | |
| Esposito et al. | Cubic phases, cubosomes and ethosomes for cutaneous application | |
| CN106726641A (en) | A kind of many vesicles of cladding D panthenols and preparation method thereof | |
| Thadanki et al. | Review on Ethosomes: A novel approach of Liposomes. | |
| KR20010083712A (en) | composition for liposome cosmetics and preparation method thereof | |
| KR102013804B1 (en) | Cosmetic composition comprising cubosome containing active ingredient | |
| KR20090020407A (en) | Nano liposome composition and cosmetic comprising nano liposome produced therefrom | |
| Nastruzzi et al. | Use ano stability of liposomes in dermatological preparations | |
| JP3834563B2 (en) | Method for producing stable nano-emulsified particles using arbutin and cosmetic composition containing nano-emulsified particles | |
| KR20190086904A (en) | Method for Manufacturing Skin Moisturizing Composition Comprising of Carriers Having Multi-Layer Structure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |